Anaptysbio (ANAB) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Anaptysbio (ANAB) over the last 12 years, with Q3 2025 value amounting to $109.8 million.
- Anaptysbio's Cash & Equivalents fell 4267.02% to $109.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.8 million, marking a year-over-year decrease of 4267.02%. This contributed to the annual value of $123.1 million for FY2024, which is 24222.16% up from last year.
- As of Q3 2025, Anaptysbio's Cash & Equivalents stood at $109.8 million, which was down 4267.02% from $44.3 million recorded in Q2 2025.
- Over the past 5 years, Anaptysbio's Cash & Equivalents peaked at $495.7 million during Q4 2021, and registered a low of $26.3 million during Q3 2023.
- For the 5-year period, Anaptysbio's Cash & Equivalents averaged around $142.2 million, with its median value being $94.6 million (2023).
- Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 8561.55% in 2022, then skyrocketed by 62858.34% in 2024.
- Anaptysbio's Cash & Equivalents (Quarter) stood at $495.7 million in 2021, then plummeted by 85.62% to $71.3 million in 2022, then crashed by 49.56% to $36.0 million in 2023, then skyrocketed by 242.22% to $123.1 million in 2024, then decreased by 10.76% to $109.8 million in 2025.
- Its last three reported values are $109.8 million in Q3 2025, $44.3 million for Q2 2025, and $98.6 million during Q1 2025.